Vimarsana
Biggest News Aggregation in the World

Page 2 - Robert Uzzo News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Robert Uzzo. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Robert Uzzo Today - Breaking & Trending Today

Fox Chase Cancer Center's Edna "Eti" Cukierman Named to Newly Created Marvin & Concetta Greenberg Chair in Pancreatic Cancer Research - Vimarsana News

Fox Chase Cancer Center's Edna "Eti" Cukierman Named to Newly Created Marvin & Concetta Greenberg Chair in Pancreatic Cancer Research

Edna “Eti” Cukierman, PhD, has been appointed to the newly created Marvin & Concetta Greenberg Chair in Pancreatic Cancer Research.

26 highly successful CEO-CFO duos - Vimarsana News

26 highly successful CEO-CFO duos

Hospital and health system CEOs and CFOs must work in unison to lead their organizations to success.

Fox Chase Cancer Center Invests in Expanding Access to Lifesaving Radiopharmaceuticals for Cancer Patients - Vimarsana News

Fox Chase Cancer Center Invests in Expanding Access to Lifesaving Radiopharmaceuticals for Cancer Patients

As the first initiative of an emerging collaboration, Fox Chase Cancer Center has invested in Nucleus RadioPharma, a company specializing in the development and distribution of radiopharmaceuticals, targeted therapies that deliver radiation directly to cancer cells.

Dr Igor Astsaturov Appointed Inaugural Holder of Paul F. Engstrom Professorship in Oncology at Fox Chase Cancer Center - Vimarsana News

Dr Igor Astsaturov Appointed Inaugural Holder of Paul F. Engstrom Professorship in Oncology at Fox Chase Cancer Center

Igor Astsaturov, MD, PhD, has been appointed inaugural holder of the Paul F. Engstrom Professorship in Oncology.

Everolimus after surgery may benefit patients with very-high-risk clear cell renal cell carcinoma - Vimarsana News

Everolimus after surgery may benefit patients with very-high-risk clear cell renal cell carcinoma

A secondary analysis from the SWOG S0931 EVEREST trial has found that in the subgroup of patients with clear-cell renal cell carcinoma (RCC) who were at very-high risk of recurrence, those who were treated with everolimus after surgery had a statistically significant improvement in recurrence-free survival compared to patients getting placebo after surgery.